TAP2 and cancer: To investigate mechanisms mediating cancer cell TAP2 downregulation in NSCLC, we evaluated the frequency of deleterious TAP2 genetic variants in human lung adenocarcinomas and squamous-cell carcinomas from The Cancer Genome Atlas (TCGA) cohort analyzed using whole exome DNA sequencing.